Top Private Equity News, Member Posts, Managed Futures Daily Indices and more!

2yrs ago Private Equity privateequitywire Views: 533

NPIF - Maven Equity Finance leads GBP2 million funding round in LCC

Submitted 13/04/2021 - 9:03am

NPIF - Maven Equity Finance, part of the Northern Powerhouse Investment Fund (NPIF) and managed by Maven Capital Partners (Maven), has led a GBP2 million funding round for LCC (Liverpool Chirochem Limited), an international chemical technology business whose products form the building blocks to the research and development of new drugs. 

The NPIF - Maven Equity Fund invested GBP1 million, alongside the GBP1 million from the Government’s Future Fund.

NPIF - Maven Equity Finance originally invested GBP500,000 in 2018 to support the company through its ‘proof of concept’ phase and establish operations in the UK and China, as well as grow its initial team to 12 employees. Today’s transaction will help the business to rapidly scale up and expand its production capacity to service its growing customer base. To date LCC has also previously received equity funding from Deepbridge Capital and Praetura Ventures totalling some GBP6m since 2015.

Since the company’s founding in 2014, LCC has produced products which provide pharmaceutical companies innovative processes for the research and development of new drugs. The company’s most notable product, 3D Chiral Scaffolds, are used by pharmaceutical companies all over the world.

LCC’s higher quality 3D compounds enable their customers to increase success probability, reduce trial costs and time and accelerate revenue generation.

Backed by a highly skilled, specialist management team, CEO Paul Colbon, a founding member of LCC, previously worked with Redx Pharma and AstraZeneca. Chairman and Director, Malcolm Stewart, has over 20 years industrial experience in speciality chemicals and advanced materials with ICI, Zeneca and Avecia and 15 years working at Board level with early-stage technology businesses servicing the Electronics and Life Science Sectors.

Paul Colbon, CEO and co-founder of LCC, says: “2020 was an outstanding year for LCC despite the challenges and continuing disruption of COVID. LCC’s stock of unique, diverse and high purity chemical compounds are expanding month on month. Securing these additional funds will enable the Team to accelerate investment in capital equipment, continuing the scale up of our production capability, enabling LCC to take advantage of the new and growing customer opportunities.”

Simon Robb, Portfolio Manager at Maven, says: “LCC is a global innovator creating specialist products that enable drug discovery and we’re delighted to continue to support such a pioneering company operating in a vital sector of the science technology space. Today’s transaction demonstrates our belief in how far the business has come and the future growth it can achieve. We look forward to working with Paul and the team as they drive the business forward.”

Asif Hamid MBE, Chair of the Liverpool City Region Local Enterprise Partnership (LEP), says: “Small businesses are the backbone of our economy and the Northern Powerhouse Investment Fund has provided valuable support to our business community since its launch in 2017. By helping innovative and ambitious companies such as LCC grow and invest, NPIF has had a fantastic impact on unlocking business potential and creating jobs in the City Region.”

Grant Peggie at British Business Bank, says: “LCC is a great example of a business that is making a real difference at the heart of our Northern Powerhouse, pushing forward innovation, creating jobs and expanding internationally. The region has a thriving Life Sciences industry and even with a year of significant disruption, it continues to be successful. NPIF will continue to support innovative businesses in the sector, providing vital investment as the UK economy bounces back.”

The Northern Powerhouse Investment Fund project is supported financially by the European Union using funding from the European Regional Development Fund (ERDF) as part of the European Structural and Investment Funds Growth Programme 2014-2020 and the European Investment Bank.

Like this article? Sign up to our free newsletter Tags Deals & Transactions Investments

Today's Private Equity Headlines:

Log In for More
Access Over 250K+ Industry Headlines, Posts and Updates
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.